







All Databases	PubMed	Nucleotide	Protein	Genome	Structure	ОМІМ	PMC	Journa	ıls I
Search PubMed		for cla	rk k and AA	V			© (0	lear	Save S
	Limit	s Preview	/Index ✓ H	listory CI	ipboard 💙	Details			
About Entrez		Summary	\	Show 20	Sort by	/ . 🔯 S	end to		
Text Version	All: 8	Review: 0 1 - 8 of 8	*		<i>.</i> *			O== :	
Entrez PubMed			N. A Ca.		d KD Objek	DV	Dalakad		e page.
Overview Help FAQ Tutorial New/Noteworthy E-Utilities		Physiologics selective exp Neuron. 2004 PMID: 151574	al propertie pression of May 27;42(4)	s of hypoth reporter gen 0:635-52.	alamic MCI	H neuron		ied wit	th
PubMed Services	□2:	Wang C, Wang	g CM, Clark I	KR, Sferra TJ	<u>.</u>		Related	Articles	, Links
Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher Clinical Queries Special Queries	Recombinant AAV serotype 1 transduction efficiency and tropism in the								
LinkOut	□3:	Clark KR.	•				Related	Articles	s, Links
My NCBI (Cubby) Related Resources Older Documents		Recent adva Kidney Int. 20 PMID: 118416	02 Jan;61 Suj	ppl 1:9-15.		ated virus	_	•	tion.
NLM Catalog NLM Gateway	□4:	Liu X, Voulga	ropoulou F, C	Chen R, Johns	on PR, Clark	KR.	Related	Articles	s, Links
TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov PubMed Central		Selective Rerecombinant Mol Ther. 200 PMID: 110203	t AAV prod 0 Oct;2(4):39	luction fron 4-403.	n stable cell		for high-	titer	
	□5:	Liu XL, Clark	KR, Johnson	PR.			Related	Articles	, Links
		Production of packaging of Gene Ther. 199 PMID: 104351	ell line and 99 Feb;6(2):2	a hybrid re 93-9.	combinant a			; a	
	□6:	Clark KR, Liu	X, McGrath.	JP, Johnson P	<u>R.</u>		Related	Articles	, Links
	Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum Gene Ther. 1999 Apr 10;10(6):1031-9. PMID: 10223736 [PubMed - indexed for MEDLINE]								
	□7:	Clark KR, Voi	ılgaropoulou	F, Johnson PF	<u>ર.</u>		Related	Articles	, Links
		A stable cell for infectivit Gene Ther. 19 PMID: 898643	ty titration (96 Dec;3(12)	of adeno-as:	sociated vir	-		es allo)WS









All Databases	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals [
Search PubMed		for job	nson p and	AAV			Go	Clear Save S		
	Limit					Details				
About Entrez	Displa	Summary	\	Show 20	Sort by	S S	end to			
Text Version	All: (6 Review: 0 1 - 6 of 6	*					One page.		
Entrez PubMed	□1:	Liu X, Voulga	ropoulou F, (Chen R, Johns	son PR, Clark k	CR.	Relate	ed Articles, Links		
Overview Help FAQ Tutorial New/Noteworthy E-Utilities		Selective Rerecombinant Mol Ther. 200 PMID: 110203	AAV prod 0 Oct;2(4):39	duction from from 94-403.			for hig	h-titer		
PubMed Services	□2:	Liu XL, Clark	KR, Johnson	ı PR.			Relate	ed Articles, Links		
Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher Clinical Queries Special Queries		Production of packaging of Gene Ther. 199 PMID: 104351	ell line and 99 Feb;6(2):2	l a hybrid re 293-9.	ecombinant a			ıg a		
LinkOut My NCB! (Cubby)	□3:	Clark KR, Liu	X, McGrath	JP, Johnson I	PR.		Relate	ed Articles, Links		
My NCBI (Cubby) Related Resources Order Documents NLM Catalog NLM Gateway TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov PubMed Central		Highly purif biologically Hum Gene The PMID: 102237	active and er. 1999 Apr	free of dete 10;10(6):103	1-9.					
	□4:	Lo WD, Qu G,	Sferra TJ, C	lark R, Chen	R, Johnson PR	<u>.</u>	Relate	ed Articles, Links		
		Adeno-association of Hum Gene The PMID: 100225	of expressi er. 1999 Jan 2	on. 20;10(2):201-		to the b	rain: dı	iration and		
•	□5:	Clark KR, Vou	lgaropoulou	F, Johnson P	<u>R.</u>		Relate	ed Articles, Links		
		A stable cell for infectivit Gene Ther. 199 PMID: 898643	y titration 96 Dec;3(12)	of adeno-as :1124-32.	ssociated viru			nes allows		
	□6:	Clark KR, Vou	lgaropoulou	F, Fraley DM	I, Johnson PR.		Relate	ed Articles, Links		
	Cell lines for the production of recombinant adeno-ass Hum Gene Ther. 1995 Oct;6(10):1329-41. PMID: 8590738 [PubMed - indexed for MEDLINE]							ociated virus.		
	Displa	ySummary		Show 20	Sort by	Se	end to	<u> </u>		

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer









All Databases PubMed Nucleotide Structure OMIM **PMC** Journals Search PubMed Go for johnson p and adeno-associated Clear History Clipboard Limits Preview/Index Details Display Summary Show 20 Sort by \Box Send to About Entrez All: 14 Review: 0 Text Version -Items 1 - 14 of 14 One page. 1: Johnson PR, Schnepp BC, Connell MJ, Rohne D, Robinson S, Entrez PubMed Related Articles, Links Overview Krivulka GR, Lord CI, Zinn R, Montefiori DC, Letvin NL, Clark Help | FAQ KR. Tutorial Novel adeno-associated virus vector vaccine restricts replication of simian New/Noteworthy immunodeficiency virus in macaques. E-Utilities J Virol. 2005 Jan;79(2):955-65. PMID: 15613324 [PubMed - indexed for MEDLINE] PubMed Services Journals Database 2: Schnepp BC, Clark KR, Klemanski DL, Pacak CA, Johnson PR. Related Articles, Links MeSH Database Single Citation Matcher Genetic fate of recombinant adeno-associated virus vector genomes in **Batch Citation Matcher** Clinical Queries muscle. **Special Queries** J Virol. 2003 Mar;77(6):3495-504. LinkOut PMID: 12610125 [PubMed - indexed for MEDLINE] My NCBI (Cubby) 3: Lewis AD, Chen R, Montefiori DC, Johnson PR, Clark KR. Related Articles, Links Related Resources Generation of neutralizing activity against human immunodeficiency virus **Order Documents** type 1 in serum by antibody gene transfer. **NLM Catalog** J Virol. 2002 Sep;76(17):8769-75. **NLM Gateway** PMID: 12163597 [PubMed - indexed for MEDLINE] **TOXNET** Consumer Health 4: Liu X, Voulgaropoulou F, Chen R, Johnson PR, Clark KR. Clinical Alerts Related Articles, Links ClinicalTrials.gov Selective Rep-Cap gene amplification as a mechanism for high-titer **PubMed Central** recombinant AAV production from stable cell lines. Mol Ther. 2000 Oct;2(4):394-403. PMID: 11020356 [PubMed - indexed for MEDLINE] 5: Beall CJ, Phipps AJ, Mathes LE, Stromberg P, Johnson PR. Related Articles, Links Transfer of the feline erythropoietin gene to cats using a recombinant adeno-associated virus vector. Gene Ther. 2000 Mar;7(6):534-9. PMID: 10757028 [PubMed - indexed for MEDLINE] 6: Sferra TJ, Qu G, McNeely D, Rennard R, Clark KR, Lo WD, Related Articles, Links Johnson PR. Recombinant adeno-associated virus-mediated correction of lysosomal storage within the central nervous system of the adult mucopolysaccharidosis type VII mouse. Hum Gene Ther. 2000 Mar 1;11(4):507-19. PMID: 10724030 [PubMed - indexed for MEDLINE] 7: Clark KR, Sferra TJ, Lo W, Qu G, Chen R, Johnson PR. Related Articles, Links

	Gene transfer into the CNS using recombinant adeno analysis of vector DNA forms resulting in sustained of J Drug Target. 1999 Dec;7(4):269-83. PMID: 10682906 [PubMed - indexed for MEDLINE]					
□8:	Liu XL, Clark KR, Johnson PR.	Related Articles, Links				
	Production of recombinant adeno-associated virus ve packaging cell line and a hybrid recombinant adenove Gene Ther. 1999 Feb;6(2):293-9. PMID: 10435114 [PubMed - indexed for MEDLINE]					
□9:	Clark KR, Liu X, McGrath JP, Johnson PR.	Related Articles, Links				
Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum Gene Ther. 1999 Apr 10;10(6):1031-9. PMID: 10223736 [PubMed - indexed for MEDLINE]						
□ 10	Lo WD, Qu G, Sferra TJ, Clark R, Chen R, Johnson PR.	Related Articles, Links				
	Adeno-associated virus-mediated gene transfer to the modulation of expression. Hum Gene Ther. 1999 Jan 20;10(2):201-13. PMID: 10022545 [PubMed - indexed for MEDLINE]	e brain: duration and				
□.11	: Clark KR, Sferra TJ, Johnson PR.	Related Articles, Links				
	Recombinant adeno-associated viral vectors mediate expression in muscle. Hum Gene Ther. 1997 Apr 10;8(6):659-69. PMID: 9113506 [PubMed - indexed for MEDLINE]	e long-term transgene				
□12	: Clark KR, Voulgaropoulou F, Johnson PR.	Related Articles, Links				
<u> </u>	A stable cell line carrying adenovirus-inducible rep for infectivity titration of adeno-associated virus vec Gene Ther. 1996 Dec;3(12):1124-32. PMID: 8986439 [PubMed - indexed for MEDLINE]					
□13	: Clark KR, Voulgaropoulou F, Fraley DM, Johnson PR.	Related Articles, Links				
	Cell lines for the production of recombinant adeno-a Hum Gene Ther. 1995 Oct;6(10):1329-41. PMID: 8590738 [PubMed - indexed for MEDLINE]	associated virus.				
□14	: Chatterjee S, Johnson PR, Wong KK Jr.	Related Articles, Links				
	Dual-target inhibition of HIV-1 in vitro by means of virus antisense vector. Science. 1992 Nov 27;258(5087):1485-8. PMID: 1359646 [PubMed - indexed for MEDLINE]	f an adeno-associated				
Display	Summary Show 20 Sort by	Send to				

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Jun 27 2005 04:57:20









All Databases	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journa	ils
Search PubMed		for clar	k kr and ad	eno-associat	ed		©o	Clear	Save S
	Limit	s Preview/I	ndex ~ H	istory Cli	pboard D	etails			
About Entrez		Summary	L.	Show 20	Sort by	S	end to		
Text Version	All:	15 Review: 0 1 - 15 of 15	<u>&</u>					One	e page.
Entrez PubMed Overview Help FAQ	□1:	Johnson PR, Sci Krivulka GR, L KR.	hnepp BC, C ord CI, Zinn	Connell MJ, Ro R, Montefiori	ohne D, Robins i DC, Letvin N	son S, L, Clark	Relate	d Articles	
Tutorial New/Noteworthy E-Utilities		Novel adeno- immunodefic J Virol. 2005 Ja	iency viru n;79(2):955-	s in macaqu ·65.	es.	stricts re	plication	on of sin	mian
PubMed Services Journals Database MeSH Database	□ 2:	PMID: 1561332 Wang C, Wang			MEDLINE		Relate	d Articles	s, Links
Single Citation Matcher Batch Citation Matcher Clinical Queries Special Queries LinkOut My NCBI (Cubby)		Recombinant murine brain. Gene Ther. 2007 PMID: 1290076	3 Aug;10(17):1528-34.		ciency a	ınd trop	ism in	the
Wiy NCBi (Cubby)	□3:	Schnepp BC, Cl	lark KR, Kle	manski DL, P	acak CA, John	son PR.	Relate	d Articles	, Links
Related Resources Order Documents NLM Catalog NLM Gateway TOXNET		Genetic fate of muscle. J Virol. 2003 M PMID: 1261012	ar;77(6):349	95-504.		rirus vec	tor gen	omes ir	l
Consumer Health Clinical Alerts ClinicalTrials.gov	□4:	Sun Y, Jin K, C Greenberg DA.	lark KR, Pee	el A, Mao XO,	Chang Q, Sin	ion RP,	Relate	d Articles	, Links
PubMed Central		Adeno-associ outcome after Gene Ther. 2003 PMID: 1257164	r transient 3 Jan;10(2):1	focal cerebr	al ischemia.	_	ene imp	roves	
	□ 5:	Lewis AD, Cher	n R, Montefi	iori DC, Johns	on PR, Clark k	<u>ζR.</u>	Relate	d Articles	, Links
•		Generation of type 1 in seru J Virol. 2002 Se PMID: 1216359	m by antil p;76(17):87	oody gene tr 69-75.	ansfer.	an immı	ınodefi	ciency [·]	virus
	□ 6:	Schnepp B, Clar	rk KR.				Relate	d Articles	, Links
		Highly purificand quantitati Methods Mol M PMID: 1198779	ion. Ied. 2002;69	:427-43. No al	bstract availab		ctors. P	reparati	on
	□7:	Clark KR.		•			Relate	d Articles	, Links

Recent advances in recombinant adeno-associated virus vector production.

	Kidney Int. 2002 Jan;61 Suppl 1:9-15. PMID: 11841606 [PubMed - as supplied by publisher]	
□8:	Liu X, Voulgaropoulou F, Chen R, Johnson PR, Clark KR.	Related Articles, Links
	Selective Rep-Cap gene amplification as a mechanism for recombinant AAV production from stable cell lines. Mol Ther. 2000 Oct;2(4):394-403. PMID: 11020356 [PubMed - indexed for MEDLINE]	or high-titer
□9:	Sferra TJ, Qu G, McNeely D, Rennard R, Clark KR, Lo WD, Johnson PR.	Related Articles, Links
	Recombinant adeno-associated virus-mediated corrections storage within the central nervous system of the adult mucopolysaccharidosis type VII mouse. Hum Gene Ther. 2000 Mar 1;11(4):507-19. PMID: 10724030 [PubMed - indexed for MEDLINE]	n of lysosomal
□10	: Clark KR, Sferra TJ, Lo W, Qu G, Chen R, Johnson PR.	Related Articles, Links
	Gene transfer into the CNS using recombinant adeno-a analysis of vector DNA forms resulting in sustained ex J Drug Target. 1999 Dec;7(4):269-83. PMID: 10682906 [PubMed - indexed for MEDLINE]	
□11	: Liu XL, Clark KR, Johnson PR.	Related Articles, Links
	Production of recombinant adeno-associated virus vect packaging cell line and a hybrid recombinant adenovirugene Ther. 1999 Feb;6(2):293-9. PMID: 10435114 [PubMed - indexed for MEDLINE]	
T 12	: Clark KR, Liu X, McGrath JP, Johnson PR.	Related Articles, Links
	Highly purified recombinant adeno-associated virus ve biologically active and free of detectable helper and wi Hum Gene Ther. 1999 Apr 10;10(6):1031-9. PMID: 10223736 [PubMed - indexed for MEDLINE]	
₹ 13	: Clark KR, Sferra TJ, Johnson PR.	Related Articles, Links
	Recombinant adeno-associated viral vectors mediate lo expression in muscle. Hum Gene Ther. 1997 Apr 10;8(6):659-69. PMID: 9113506 [PubMed - indexed for MEDLINE]	ng-term transgene
□14	: Clark KR, Voulgaropoulou F, Johnson PR.	Related Articles, Links
	A stable cell line carrying adenovirus-inducible rep and for infectivity titration of adeno-associated virus vector Gene Ther. 1996 Dec;3(12):1124-32. PMID: 8986439 [PubMed - indexed for MEDLINE]	
□15	: Clark KR, Voulgaropoulou F, Fraley DM, Johnson PR.	Related Articles, Links
	Cell lines for the production of recombinant adeno-asso Hum Gene Ther. 1995 Oct;6(10):1329-41. PMID: 8590738 [PubMed - indexed for MEDLINE]	ociated virus.
Display	Summary Show 20 Sort by Se	nd to

Write to the Help Desk

```
FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 14:53:47 ON 22 JUL 2005
            8149 S AAV OR RAAV OR (ADENO-ASSOCIATED ADJ VIRUS?)
L1
               4 S ((REP 78) (S) (REP 68)) OR (REP 78/68) OR ((REP ADJ 78) (2W)
L2
               4 DUP REM L2 (0 DUPLICATES REMOVED)
L3
L4
             334 S L1 (P) (REP (3A) EXPRESS?)
            290 S L4 (P) CELL
129 S L5 (P) HELPER
L5
L6
               2 S L6 (P) ((REP 52) OR (REP 40))
L7
L8
               8 S L5 (P) ((SIMIAN) OR (SV-20))
L9
               2 DUP REM L8 (6 DUPLICATES REMOVED)
              99 S L1 (P) ((SIMIAN) OR (SV-20))
L10
L11
              42 DUP REM L10 (57 DUPLICATES REMOVED)
L12
              11 S L1 (P) ((SIMIAN ADENOVIR?) OR (SV-20))
               8 DUP REM L12 (3 DUPLICATES REMOVED)
L13
               1 S L1 (P) FRHL?
L14
               1 S L1 (P) SV20
1 S L1 (P) PERC.6
L15
L16
               2 S L1 (P) MRC-5
L17
L18
               2 S L1 AND MRC-5
L19
               5 S L1 AND WI-38
               5 DUP REM L19 (0 DUPLICATES REMOVED)
L20
              47 DUP REM L6 (82 DUPLICATES REMOVED)
L21
             10 S L21 AND P5
T-22
```

- IN Clark, Kelly Reed; Johnson, Philip R., Jr.
- SO PCT Int. Appl., 34 pp. CODEN: PIXXD2
- TI Recombinant adeno-associated virus production using recombinant adenovrus or vaccinia virus expressing AAV rep52 and rep40 gene
- AB The present invention relates to methods and materials for recombinant adeno-assocd. virus prodn. More particularly, the invention relates to use of recombinant adenovirus encoding adeno-assocd. virus protein in recombinant adeno-assocd. virus prodn. methods. In contrast to previous methods which rely on decreasing the expression of Rep 78 and 68 proteins, the present inventors contemplate that rAAV can be better produced not by intentionally decreasing expression of Rep 78 and 68 proteins, but instead by intentionally overexpressing Rep 52 and Rep 40 proteins and/or providing supplemental Rep 52 and Rep 40 proteins. The invention thus provides an infectious recombinant adeno-assocd. virus-producing cell that contains a rAAV genome, AAV rep-cap proteins and AAV helper functions and that overexpresses AAV Rep 52 and Rep 40 proteins while expressing AAV Rep 78 and Rep 68 proteins at about the level as if controlled by the p5 promoter in native conformation.
- IN Chen, Haifeng; Kurtzman, Gary
- SO PCT Int. Appl., 84 pp.
- CODEN: PIXXD2
- TI Production of recombinant AAV using adenovirus vectors comprising AAV rep/cap genes and use thereof
- AB This invention relates to novel adenoviruses useful in the prodn. of high titers of recombinant adeno-assocd. virus (rAAV) comprising a foreign DNA insert and methods of making these adenoviruses. The adenovirus comprises the AAV rep gene in which the p5 promoter of rep is replaced by a minimal promoter or by no promoter. The invention also provides methods of producing high levels of rAAV as a substantially homogeneous prepn. and compns. of rAAV.
- AU Kube, Dagmar M.; Ponnazhagan, Selvarangan; Srivastava, Arun [Reprint author]
- SO Journal of Virology, (1997) Vol. 71, No. 10, pp. 7361-7371. CODEN: JOVIAM. ISSN: 0022-538X.
- TI Encapsidation of adeno-associated virus type 2 Rep proteins in wild-type and recombinant progeny virions: Rep-mediated growth inhibition of primary human cells.
- AB The adeno-associated virus type 2 (AAV) arrests the growth of primary human fibroblasts in vitro at high particle-to-cell ratios. To test the role of AAV gene expression in the observed growth inhibition, primary human cells were infected, under identical conditions,

with wild-type (wt) AAV or with recombinant AAV that lacked all viral promoters and coding sequences. Significant, dose-dependent growth inhibition of primary human cells was observed with both wt and recombinant AAV at particle-to-cell ratios equal to or exceeding 10-4. In contrast, neither virus affected the growth of immortalized human cells even at a 10-fold-higher particle-to-cell ratio. AAV-induced growth arrest could be overcome by reculturing cells after treatment with trypsin. Even after reculturing, cells still harbored the proviral AAV genome. Thus, neither integration nor expression of the AAV genome appears to be required for the virus-induced growth-inhibitory effect on primary human cells. growth-inhibitory effect of AAV was hypothesized to be mediated by virion-associated AAV Rep proteins, since these proteins have been reported to inhibit cellular DNA synthesis. Rep proteins tightly associated with wt as well as recombinant AAV could be detected on Western blots. Coinfection by adenovirus was necessary and sufficient for ample replication of recombinant AAV genomes lacking the rep gene. Although wt AAV-like particles arose during production of the recombinant AAV stocks, their low-titer levels were insufficient to cause the observed growth inhibition. AAV rep gene expression from these contaminating particles was not required for replication of the recombinant AAV genomes, which could be detected even in the absence of de novo Rep protein synthesis. Exposure of recombinant AAV to anti-AAV Rep protein antibodies did not abrogate viral infectivity. These results suggest that biologically active Rep proteins are encapsulated in mature progeny AAV particles. AAV Rep protein-mediated growth inhibition of primary human cells has implications in the use of AAV-based vectors in human gene therapy.

- IN Flotte, Terence R.; Carter, Barrie J.; Guggino, William B.; Sollow, Rikki
 SO PCT Int. Appl., 50 pp.
 CODEN: PIXXD2
- TI Generation of high titers of recombinant adeno-associated virus (AAV) vectors for gene therapy
- AB AAV vectors may have utility for gene therapy but heretofore a significant obstacle has been the inability to generate sufficient quantities of such recombinant vectors in amts. that would be clin. useful for human gene therapy application. Stable, helper-free AAV packaging cell lines have been elusive, aminly due to the activities of Rep protein, which down-regulates its own expression and reverses cellular immortalization. This invention provides packaging systems and processes for packaging AAV vectors that effectively circumvent these problems by replacing the AAV p5 promoter with a heterologous promoter and that allow for substantially increased packaging efficiency. Thus, in packaging plasmid pRS5, the AAV p5 promoter is replaced by a heterologous promoter so that expression of the rep gene polypeptide does not neg. autoregulate its own synthesis; pRS5 contains the entire AAV coding sequence within the AAV nucleotide sequence from nucleotide 263 to 4491 which includes the rep coding sequence for Rep 78 and Rep 68 operably linked to the heterologous HIV-LTR promoter and expresses Rep 52 and Rep 40 from the AAV p19 promoter and the AAV capsid proteins from the p40 promoter. The pAAVp5neo construct was used as a vector construct for testing each of the packaging techniques. Human 293-31 cells were grown in Eagle's Modified Essential Medium with 10% fetal calf serum at 37 deg in 5% CO2. The 293 cell line was used for both packaging of vector prepns. and for neo transduction expts. to verify the neo-transducing titers. The pRS5 construct was used to package the pAAVp5neo vector plasmid by cotransfection into adenovirus type 5 (Ad5)-infected 293 cells. An AAV-CFTR vector, pTRF42, contg. the cystic fibrosis transmembrane conductance regulator cDNA expressed from an AAV ITR as the promoter in the absence of a selectable marker was used to generate stable vector producer lines in the 293 cell line by cotransfection with a pSVneo plasmid. This vector was rescuable from the stable cell lines, and the rescued vector was intact and unrearranged. Examples are given on packaging of AAV vectors encoding CFTR, integration of the lacZ gene into lung airway epithelium, expression of the lacZ gene in mice, and integration and expression of the CD44 gene in lung carcinoma cells.

- IN Samulski, Richard J.; Xiao, Xiao; Snyder, Richard
- SO PCT Int. Appl., 53 pp.

CODEN: PIXXD2

- TI Methods for increasing the efficiency of recombinant adeno-associated virus product
- High-titer stocks of recombinant adeno-assocd. virus (rAAV) are AB produced in increased yield by regulation of expression of the AAV gene rep and capsid proteins. Low-level expression of the AAV gene rep protein increases the prodn. of AAV viral capsid protein with a resultant packaging efficiency improvement resulting in prodn. of higher titer recombinant viral stocks. Vectors for rAAV direct the expression of AAV gene rep and capsid proteins and are used for the prodn. of novel stable cell lines capable of generating high-titer rAAV vectors. Methods are described for regulating the expression of the AAV rep gene at the transcriptional and post-translational level. Helper plasmids AAV/Ad, CMV/AAV, HIV/ AAV, SV/AAV, and ACG-2 were constructed expressing an entire AAV helper plasmid coding sequence including promoter p5, the same sequence with p5 promoter replaced by cytomegalovirus immediate early promoter, by the HIV long terminal repeat promoter, by the SV40 late promoter, and including the promoter p5 but replacement of the initiation codon ATG with the less efficient codon ACG, resp. Human 293 cells were transfected with different ratios of rAAV vector:helper plasmid. There was efficient gene rep expression from heterologous promoters in the absence of adenovirus. Helper plasmids pCMV/AAV and pHIV/AAV generated the lowest rAAV yields, even though they produced the highest Rep levels. Overexpression of gene rep inhibited rAAV DNA replication and capsid gene expression.
- IN Colosi, Peter
- SO U.S., 19 pp., Cont.-in-part of Ser. No. US 1998-107708, filed on 30 Jun 1998 CODEN: USXXAM
- TI Helper functions for adeno-associated virus for high-efficiency generation of wild-type-free virus carrying foreign genes
- AB Helper functions for the packaging of adeno-assocd. virus (AAV) that do not allow the generation pseudowild AAV virions are described. The helper functions include the AAV rep and cap genes expressed from the p19 and p40 promoters but lacking a p5 promoter because of deletion of the p5 TATA box. In addn., inverted terminal repeats are deleted from expression constructs for the rep and cap genes. Host cells expressing these genes and the manuf. of transgenic virions are described. A helper plasmid of the invention, pHLP19, carrying the rep and cap genes and the p19 and p40 promoters gave a yield of AAV that was 200-300% greater than that from prior art helper vectors with no detectable generation of pseudowild type virus.
- IN Natsoulis, George; Colosi, Peter; Kurtzman, Gary
- SO U.S., 14 pp., Cont.-in-part of U.S. Ser. No. 688,648. CODEN: USXXAM
- TI High-efficiency adeno-associated virus helper functions for improved gene therapy
- The present invention provides methods and compns. for producing high titer prepns. of recombinant AAV ("rAAV") virions.

 The compns. of the present invention include AAV helper function systems and host cells. The present invention also includes methods of using AAV helper function vectors that effect the prodn. of only small amts. of the long forms of Rep protein, and rAAV virions produced by such methods.

 Cells transfected with pW1909 comprising rep and cap coding regions and a downstream p5 promoter sandwiched between two Flip Recombination Target (FRT) sites produced very little of the long forms of Rep, as well as more of the short forms of Rep, than other AAV helper function vectors. Introduction of an efficient polyadenylation site between the transcriptional start site and the first codon in the coding sequence of the long forms of Rep protein also decreased expression of the long forms of Rep and

increased expression of the short forms. Prodn. of only small amts. of the long forms of Rep protein provide for higher titer rAAV virion prodn.

- AU Li J; Samulski R J; Xiao X
- SO Journal of virology, (1997 Jul) 71 (7) 5236-43. Journal code: 0113724. ISSN: 0022-538X.
- TI Role for highly regulated rep gene expression in adeno-associated virus vector production.
- AB Recent success achieving long-term in vivo gene transfer without a significant immune response by using adeno-associated virus (AAV) vectors (X. Xiao, J. Li, and R. J. Samulski, J. Virol. 70:8098-8108, 1996) has encouraged further development of this vector for human gene therapy. Currently, studies focus on the generation of high-titer vectors by using the two-plasmid helper-vector system in adenovirus (Ad)-infected cells. To examine the effects of the AAV replication (rep) genes on recombinant AAV (rAAV) vector production, we have constructed a series of AAV helper plasmids that contain strong heterologous promoters in place of the endogenous p5 promoter. Although high-level rep gene expression was achieved, rAAV DNA failed to replicate in the absence of Ad infection. Moreover, unregulated overexpression of Rep78/68 led to substantially lower rAAV yields in the presence of Ad (10(4-5) versus 10(7-8)). In contrast, under similar conditions, reduced Rep78/68 expression resulted in much higher rAAV yields (10(9)). Molecular characterization showed that overexpression of the rep gene decreased rAAV DNA replication and severely inhibited capsid (cap) gene expression. Interestingly, a reduced rep level enhanced cap gene expression and supported normal rAAV DNA replication. These studies suggest a critical role for regulated rep gene expression in rAAV production and have facilitated the development of a new AAV helper plasmid that increases vector production eightfold over currently used constructs.
- AU Conway J E; Zolotukhin S; Muzyczka N; Hayward G S; Byrne B J

Journal of virology, (1997 Nov) 71 (11) 8780-9. Journal code: 0113724. ISSN: 0022-538X.

- TI Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap.
- Recombinant adeno-associated virus (AAV) type 2 (rAAV) vectors have recently been shown to have great utility as gene transfer agents both in vitro and in vivo. One of the problems associated with the use of rAAV vectors has been the difficulty of large-scale vector production. Low-efficiency plasmid transfection of the rAAV vector and complementing AAV type 2 (AAV -2) functions (rep and cap) followed by superinfection with adenovirus has been the standard approach to rAAV production. The objectives of this study were to demonstrate the ability of a recombinant herpes simplex virus type 1 (HSV-1) amplicon expressing AAV-2 Rep and Cap to support replication and packaging of rAAV vectors. HSV-1 amplicon vectors were constructed which contain the AAV-2 rep and cap genes under control of their native promoters (p5, p19, and p40). An HSV-1 amplicon vector, HSV-RC/KOS or HSV-RC/d27, was generated by supplying helper functions with either wild-type HSV-1 (KOS strain) or the ICP27-deleted mutant of HSV-1, d27-1, respectively. Replication of the amplicon stocks is not inhibited by the presence of AAV-2 Rep proteins, which highlights important differences between HSV-1 and adenovirus replication and the mechanism of providing helper function for productive AAV infection. Coinfection of rAAV and HSV-RC/KOS resulted in the replication and amplification of rAAV genomes. Similarly, rescue and replication of rAAV genomes occurred when rAAV vector plasmids were transfected into cells followed by HSV-RC/KOS infection and when two rAAV proviral cell lines were infected with HSV-RC/KOS or HSV-RC/d27. Production of infectious rAAV by rescue from two rAAV proviral cell lines has also been achieved with HSV-RC/KOS and HSV-RC/d27. The particle titer of rAAV produced with HSV-RC/d27 is equal to that achieved by supplying rep and cap by transfection followed by adenovirus superinfection. Importantly, no detectable

wild-type AAV-2 is generated with this approach. These results demonstrate that an HSV-1 amplicon expressing the AAV-2 genes rep and cap along with HSV-1 helper functions supports the replication and packaging of rAAV vectors in a scaleable process.

- AU Wang X S; Srivastava A
- SO Journal of virology, (1998 Jun) 72 (6) 4811-8. Journal code: 0113724. ISSN: 0022-538X.
- TI Rescue and autonomous replication of adeno-associated virus type 2 genomes containing Rep-binding site mutations in the viral p5 promoter.
- AB The Rep proteins encoded by the adeno-associated virus type 2 (AAV) play a crucial role in the rescue, replication, and integration of the viral genome. In the absence of a helper virus, little expression of the AAV Rep proteins occurs, and the AAV genome fails to undergo DNA replication. Since previous studies have established that expression of the Rep78 and Rep68 proteins from the viral p5 promoter is controlled by the Rep-binding site (RBS) and the YY1 factor-binding site (YBS), we constructed a number of recombinant AAV plasmids containing mutations and/or deletions of the RBS and the YBS in the p5 promoter. These plasmids were transfected in HeLa or 293 cells and analyzed for the potential to undergo AAV DNA rescue and replication. Our studies revealed that (i) a low-level rescue and autonomous replication of the wild-type AAV genome occurred in 293 but not in HeLa cells; (ii) mutations in the RBS resulted in augmented expression from the p5 promoter, leading to more efficient rescue and/or replication of the AAV genome in 293 but not in HeLa cells; (iii) little rescue and/or replication occurred from plasmids containing mutations in the YBS alone in the absence of coinfection with adenovirus; (iv) expression of the adenovirus E1A gene products was insufficient to mediate rescue and/or replication of the AAV genome in HeLa cells; (v) autonomously replicated AAV genomes in 293 cells were successfully encapsidated in mature progeny virions that were biologically active in secondary infection of HeLa cells in the presence of adenovirus; and (vi) stable transfection of recombinant AAV plasmids containing a gene for resistance to neomycin significantly affected stable integration only in 293 cells, presumably because rescue and autonomous replication of the AAV genome from these plasmids occurred in 293 cells but not in HeLa or KB cells. These data suggest that in the absence of adenovirus, the AAV Rep protein-RBS interaction plays a dominant role in down-regulating viral gene expression from the p5 promoter and that perturbation in this interaction is sufficient to confer

autonomous replication competence to AAV in 293 cells.